कृपया अन्य खोज का प्रयास करें
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications. It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-1703 for autoimmune indications; SHR0410, Imrecoxib, Remimazolam, and SHR8554 for pain; Oteseconazole and HRS9950 for anti-infection; and SHR8028, SHR8058, SHR-1707, and SHR-1222 for other indications. The company was founded in 1970 and is based in Lianyungang, China.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Piao Yang Sun | 65 | 2003 | Chairman of the Board of Directors |
Guo Qiang Xiong | 47 | 2013 | Employee Representative Member of the Supervisory Committee |
Jie Ping Sun | 53 | 2003 | Deputy GM & Director |
Hong Bin Dai | 47 | 2003 | GM & Director |
Lian Shan Zhang | 61 | 2012 | Deputy GM & Director |
Kai Hong Yuan | 58 | 2023 | Chairman of the Supervisory Board |
Jiahong Dong | 62 | 2021 | Independent Director |
Congzhao Guo | 50 | 2020 | Director |
Jin Yun Sun | 51 | 2023 | Independent Director |
Qingsheng Zeng | 48 | 2023 | Independent Director |
Ningjun Jiang | 62 | 2023 | Deputy GM & Director |
Yu Xu | 30 | 2022 | Employee Representative Supervisor |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है